De Grandis, Giovanni;
Brass, Irina;
Farid, Suzanne S;
(2022)
Is regulatory innovation fit for purpose? A case study of adaptive regulation for advanced biotherapeutics.
Regulation & Governance
10.1111/rego.12496.
(In press).
Preview |
Text
Brass_Is regulatory innovation fit for purpose_ A case study of adaptive regulation for advanced biotherapeutics_AOP.pdf Download (395kB) | Preview |
Abstract
The need to better balance the promotion of scientific and technological innovation with risk management for consumer protection has inspired several recent reforms attempting to make regulations more flexible and adaptive. The pharmaceutical sector has a long, established regulatory tradition, as well as a long history of controversies around how to balance incentives for needed therapeutic innovations and protecting patient safety. The emergence of disruptive biotechnologies has provided the occasion for regulatory innovation in this sector. This article investigates the regulation of advanced biotherapeutics in the European Union and shows that it presents several defining features of an adaptive regulation regime, notably institutionalized processes of planned adaptation that allow regulators to gather, generate, and mobilize new scientific and risk evidence about innovative products. However, our in-depth case analysis highlights that more attention needs to be paid to the consequences of the introduction of adaptive regulations, especially for critical stakeholders involved in this new regulatory ecosystem, the capacity and resource requirements placed on them to adapt, and the new tradeoffs they face. In addition, our analysis highlights a deficit in how we currently evaluate the performance and public value proposition of adaptive regulations vis-à-vis their stated goals and objectives.
| Type: | Article |
|---|---|
| Title: | Is regulatory innovation fit for purpose? A case study of adaptive regulation for advanced biotherapeutics |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1111/rego.12496 |
| Publisher version: | https://doi.org/10.1111/rego.12496 |
| Language: | English |
| Additional information: | © 2022 The Authors. Regulation & Governance published by John Wiley & Sons Australia, Ltd. This is an open access article under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/). |
| Keywords: | adaptive regulation, advanced therapy medicinal products, biotherapeutics, health policy, innovation, regulatory change |
| UCL classification: | UCL > Provost and Vice Provost Offices > UCL BEAMS > Faculty of Engineering Science UCL > Provost and Vice Provost Offices > UCL BEAMS > Faculty of Engineering Science > STEaPP UCL > Provost and Vice Provost Offices > UCL BEAMS UCL |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10155897 |
Loading...
Loading...Loading...| 1. |  United States | 13 |
| 2. |  United Kingdom | 7 |
| 3. |  Germany | 4 |
| 4. |  Japan | 2 |
| 5. |  China | 2 |
| 6. |  Indonesia | 1 |
| 7. |  Russian Federation | 1 |
| 8. |  Australia | 1 |
| 9. |  Kuwait | 1 |
Archive Staff Only
 |
View Item |
